LEUKOCARE signs cooperation agreement with Sterigenics

19-Nov-2010 - Germany

Leukocare AG announced the signing of a cooperation agreement with Sterigenics. As part of this cooperation, LEUKOCARE plans to use their Stabilizing and Protecting Solutions (SPS) technology together with Sterigenics’ irradiation expertise in order to establish new sterilization procedures for biotherapeutics, such as therapeutic antibodies. The project will aim to significantly improve the sterility and security for patients receiving biotherapeutics, as well as simplifying production processes and cost reductions.

At the same time as this collaboration, LEUKOCARE also announced the closing of a EUR 1.6 Million financing. LEUKOCARE’s existing group of private investors as well as the German state-owned bank KfW, which has been a shareholder in LEUKOCARE since 2006, participated in this capital increase. The investment strengthens LEUKOCARE’s financial position and paves the way for the next strategic steps in its development.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous